RBP4 and diabetes mellitus: Liraglutide, one of the glucagon-like peptide-1 (GLP-1) analogs that could decrease post-prandial glucose level by regulating incretin in type 2 diabetes, reduced RBP4 gene expression in adipose tissue in mice, which might contribute to the reduction of cardiovascular risk in diabetes (24).